Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with significant mortality and morbidity. Approval of antifibrotic therapy has ameliorated disease progression, but therapy response is heterogeneous and to date, adequate biomarkers predicting therapy response are lacking. In recent years...

Descripción completa

Detalles Bibliográficos
Autores principales: Seeliger, Benjamin, Carleo, Alfonso, Wendel-Garcia, Pedro David, Fuge, Jan, Montes-Warboys, Ana, Schuchardt, Sven, Molina-Molina, Maria, Prasse, Antje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428132/
https://www.ncbi.nlm.nih.gov/pubmed/36059968
http://dx.doi.org/10.3389/fphar.2022.837680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428132/
https://www.ncbi.nlm.nih.gov/pubmed/36059968
http://dx.doi.org/10.3389/fphar.2022.837680

Ejemplares similares